Redeye comments on Scandion Oncology’s Q3 2024 report, and we judge a potential partnership or similar is its best hope of advancing SCO-101’s clinical development. We judge potential partners have considerable negotiating leverage, and we lower our deal estimates to account for Scandion’s weak negotiating position. If Scandion cannot find a partner, we perceive an increasing risk of our bear case materialising.